

b) treating said cells with an inhibitory composition for a time sufficient to suppress [Ig]immunoglobulin production; and

2
c) reintroducing said cells to said patient.

3
β. (Amended) A method according to claim [1 or] 2 wherein said inhibitory composition comprises IL-2.

3
4. (Amended) A method according to claim [1 or] 2 wherein said inhibitory composition comprises a mixture of IL-2 and TGF-β.

4
5. (Amended) A method according to claim [1 or] 2 wherein said inhibitory composition comprises a CD2 activator.

REMARKS

Claims 2-6 are pending in this application. An Appendix of Pending Claims is attached for the Examiner's convenience.

Claim Objections:

Claim 2 is objected to because "peripheral" is a misspelling. Claim 2 has been amended to correct the misspelling of the word "peripheral".

Claims 3-5 are objected to as being dependent on non elected claim 1. Claims 3-5 have been amended to depend from claim 2.

Applicants respectfully request that the objections be withdrawn.

Rejection Under 35 U.S.C. § 112, first paragraph:

Claims 2-6 are rejected under 35 U.S.C. § 112, first paragraph, for lack of enablement. Specifically, the Examiner asserts that the specification is not enabled for all types of autoimmune diseases.